BPC-157 + TB-500
A research blend pairing BPC-157's vascular mechanism with TB-500's cell mobilization. BPC-157 upregulates VEGFR2 to drive new blood vessel formation at the repair site. TB-500 sequesters G-actin to regulate cytoskeletal dynamics, enabling cells to migrate into the repair zone — and mobilizes endothelial progenitor cells that directly populate the vasculature BPC-157 builds. Two independent pathways, one repair outcome.
Supply the vessels.
Move the cells.
A focused two-peptide research blend pairing BPC-157’s VEGFR2-driven angiogenesis with TB-500’s actin-mediated cell mobilization. Two independent mechanisms that address the two rate-limiting steps of tissue repair: vascular supply and cellular migration.
Sikiric et al. Curr Pharm Des 2018 · Goldstein et al. Expert Opin Biol Ther 2012. All data from peer-reviewed literature. For Research Use Only — Not for Human Consumption.
Manufactured in US
US-formulated & filled
Endotoxin Tested
<0.05 EU/mL both peptides
Independently Tested
Horizon Analytical · 6-panel COA
Same Day Shipping
Order by 3PM PST
BPC-157 and TB-500 are supplied exclusively for qualified in vitro laboratory research. Not for human administration.
Both compounds are research-grade synthetic peptides supplied under research use only (RUO) designation. Neither BPC-157 nor TB-500 is approved by the FDA for any therapeutic indication. By purchasing, the buyer represents they are a qualified researcher using these compounds solely for lawful in vitro laboratory research. Not drugs, dietary supplements, food, or medical devices. For Research Use Only — Not for Human Consumption.
Two peptides.
Two mechanisms.
BPC-157 and TB-500 are the two most co-researched tissue repair peptides in the research peptide category — because their mechanisms are genuinely complementary. BPC-157 is primarily a vascular driver; TB-500 is primarily a cell mobilizer. They share no primary receptor or signaling molecule.
BPC-157
Body Protection Compound — 15 AA
Vascular BuilderA 15-amino acid pentadecapeptide derived from a protective protein in human gastric juice. Uniquely resistant to enzymatic degradation. Upregulates VEGFR2 receptor density on endothelial cells — amplifying existing VEGF signal to drive new capillary formation. Also activates FAK-paxillin signaling for fibroblast migration and modulates eNOS for nitric oxide production. Most extensively studied in tendon, ligament, GI, and muscle repair models.
15 AA
Pentadecapeptide
VEGFR2
Primary target
FAK
Cell migration
eNOS
NO modulation
TB-500
Thymosin Beta-4 Fragment — 43 AA
Cell MobilizerA 43-amino acid synthetic peptide based on the active region of thymosin beta-4 — a naturally occurring protein present in virtually all human cells. Its primary mechanism is G-actin sequestration: binding monomeric G-actin in a 1:1 ratio to regulate actin polymerization dynamics. This controls cell motility, wound edge migration, and tissue remodeling. Also mobilizes endothelial progenitor cells from bone marrow to supplement BPC-157’s angiogenic activity.
43 AA
Actin-binding motif
G-actin
1:1 sequestration
EPC
Progenitor recruit.
~4963
Daltons MW
Why these two
together.
Tissue repair has two rate-limiting steps: establishing a vascular supply and getting the right cells to the repair site. BPC-157 solves the first. TB-500 solves the second. Neither pathway is redundant — and crucially, TB-500’s EPC mobilization amplifies BPC-157’s angiogenic effect by supplying progenitor cells to populate the new vasculature.
BPC-157 — Vascular Infrastructure
Upregulates VEGFR2 density → existing VEGF produces higher angiogenic output → new capillary formation via endothelial migration and lumen formation. Also activates FAK-paxillin for fibroblast organization and eNOS for vasodilatory NO. Provides the blood supply that the repair site requires.
TB-500 — Cellular Deployment
Sequesters G-actin to regulate cytoskeletal dynamics → enabling keratinocytes, fibroblasts, and endothelial cells to migrate into the repair zone. Mobilizes endothelial progenitor cells (EPCs) from bone marrow — directly supplementing BPC-157’s angiogenic mechanism with fresh vascular progenitors. Moves cells to where BPC-157 has prepared the vascular architecture.
Pathway Convergence
Complementary Repair Protocol
BPC-157 supplies the vascular infrastructure → TB-500 deploys the cells. Independent mechanisms, shared outcome: organized tissue repair with adequate perfusion and populated cellular architecture.
Independent pathways,
shared endpoint.
BPC-157 and TB-500 share no primary receptor or signaling molecule. Their mechanisms are orthogonal — which is exactly what makes the combination meaningful.
| Mechanism | BPC-157 | TB-500 |
|---|---|---|
| Primary mechanism | VEGFR2 / FAK / eNOS | G-actin sequestration |
| Angiogenesis | ✓ Primary driver | ✓ EPC mobilization |
| Cell migration | ✓ Endothelial cells | ✓ Primary driver |
| Wound closure | ✓ Vascular | ✓ Re-epithelialization |
| Anti-inflammatory | ✓ Cytokine balance | ✓ Resolution |
| Fibroblast activity | ✓ Primary driver | ✓ Migration support |
| NO signaling | ✓ eNOS modulation | Indirect |
| Tissue types | Tendon, gut, muscle, skin | Skin, muscle, cardiac, cornea |
| Sikiric et al. Curr Pharm Des 2018 · Goldstein et al. Expert Opin Biol Ther 2012 · Chang et al. J Appl Physiol 2011. Preclinical data — research use only. | ||
What the blend
is studied for.
Four primary research domains where BPC-157 and TB-500’s complementary mechanisms are simultaneously relevant.
Tendon & Ligament Repair
BPC-157’s FAK-paxillin activation drives fibroblast outgrowth and organization. TB-500’s actin regulation enables fibroblast migration into the repair site. Together: fibroblasts recruited (TB-500) and organized into collagen-producing units (BPC-157). Endpoints: collagen fibril organization, tensile strength, fibroblast density.
Wound Healing & Skin Repair
TB-500 drives keratinocyte and fibroblast migration for re-epithelialization. BPC-157 provides angiogenesis to vascularize the healing wound bed. In rat wound models: TB-500 achieved 42–61% increased re-epithelialization; BPC-157 enhanced capillary density. Standard endpoints: wound closure rate, TEWL, histological re-epithelialization, vessel density.
Skeletal Muscle & Ischemia
BPC-157 restores blood flow to ischemic muscle via VEGFR2 (vessel density 180% baseline by day 14 in ischemic models). TB-500 mobilizes EPCs to populate new vasculature and promotes satellite cell activity. Combined: vascular restoration with cellular repopulation. Endpoints: capillary density, functional recovery, myofiber integrity.
Angiogenesis & Vascular Remodeling
BPC-157 upregulates VEGFR2 for sprouting angiogenesis and arteriogenesis. TB-500 mobilizes bone marrow EPCs to physically build the new vessel network. Both pathways measured simultaneously: tube formation assay, VEGFR2 western blot, EPC quantification by flow cytometry, capillary density histomorphometry.
All research endpoints from peer-reviewed preclinical literature. Not Trident Labs claims. Research use only.
Full specification
of each component.
157
BPC-157
Body Protection Compound-157
| Sequence | GEPPPGKPADDAGLV |
| CAS | 137525-51-0 |
| MW | 1,419.53 Da |
| Formula | C62H98N16O22 |
| Mechanism | VEGFR2 → angiogenesis · FAK-paxillin → migration · eNOS → NO |
| Purity | ≥99% HPLC · Horizon Analytical |
| Storage | -20°C lyophilized · 4°C in solution 7–14 days |
500
TB-500
Thymosin Beta-4 Fragment
| AA Count | 43 amino acids · actin-binding motif |
| CAS | 77591-33-4 |
| MW | ~4,963 Da |
| Formula | C212H350N56O78S |
| Mechanism | G-actin sequestration (1:1) → actin polymerization → cell motility → EPC recruitment |
| Purity | ≥99% HPLC · Horizon Analytical |
| Storage | -20°C lyophilized · 4°C in solution 7 days |
For Research Use Only — Not for Human Consumption. BPC-157 and TB-500 are research-grade compounds supplied exclusively for in vitro laboratory research. Not approved drugs. Not dietary supplements, food, or medical devices. By purchasing, the buyer represents they are qualified researchers using these compounds for lawful in vitro research only.
Indexed research on BPC-157 + TB-500.
Independent peer-reviewed studies. Not Trident Labs claims. For Research Use Only.
BPC 157 and Standard Angiogenic Growth Factors — VEGFR2, FAK-Paxillin, eNOS
Seiwerth S, Rucman R, Turkovic B, Sever M, et al.
Comprehensive review establishing BPC-157’s angiogenic mechanism. VEGFR2 upregulation, FAK-paxillin phosphorylation for endothelial migration, and dual eNOS activation via VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS pathways. Reviews tissue healing across tendon, ligament, muscle, and GI. Distinguishes BPC-157 mechanism from standard VEGF administration: receptor sensitization vs growth factor addition. Curr Pharm Des 2018;24(18):1972–1989.
Thymosin β4 (TB-500): A Multi-Functional Regenerative Peptide
Goldstein AL, Hannappel E, Sosne G, Kleinman HK.
Comprehensive review establishing TB-500 as the major actin-sequestering peptide in cells. G-actin binding in 1:1 ratio regulates cytoskeletal dynamics for cell motility. Reviews wound healing, cardiac repair, corneal repair, and neurological applications. Rat wound healing: 42–61% increased re-epithelialization with enhanced collagen deposition. EPC mobilization from bone marrow for vascular remodeling. Expert Opin Biol Ther 2012;12(1):37–51. PMID: 22073940.
BPC-157 FAK-Paxillin Phosphorylation and Fibroblast Outgrowth in Tendon Repair
Chang CH, Tsai WC, Hsu YH, Pang JH.
Dose-dependent FAK and paxillin phosphorylation in BPC-157-treated tendon fibroblasts. F-actin formation by FITC-phalloidin staining. Cell migration significantly enhanced in scratch assay. Tendon explant outgrowth dramatically increased. Provides cellular mechanism for BPC-157’s tendon healing: FAK-paxillin activation drives the fibroblast migration that TB-500 further amplifies via actin regulation. J Appl Physiol 2011;110(2):309–314. PMID: 21071594.
TB-500 / Thymosin Beta-4: EPC Mobilization and Wound Healing via Actin Sequestration
Sosne G, Kleinman HK, et al.
Characterization of TB-500 wound healing mechanisms. G-actin sequestration enables keratinocyte and fibroblast migration. EPC mobilization from bone marrow for vascular building — directly complementing BPC-157’s VEGFR2-driven capillary formation. Anti-inflammatory via IL-8 and NF-κB suppression. Cardiac repair and corneal healing documented as additional endpoint areas. The EPC mobilization mechanism is the direct amplification point where TB-500 and BPC-157 converge. Ann NY Acad Sci 2010. PMID referenced.
BPC-157 Enhances Wound Healing with Angiogenesis in Alkali-Burn Model
Huang T, Zhang K, Sun L, et al.
Alkali-burn wound healing study. In vitro: HUVEC proliferation, migration, and tube formation increased with VEGFR2 upregulation measured by western blot. In vivo: accelerated wound healing with increased neovascularization histomorphometry. First study with direct in vitro VEGFR2 measurement. In the context of BPC-157+TB-500 research: the in vitro angiogenesis endpoint is directly measurable alongside TB-500’s actin-mediated cell migration. Drug Des Devel Ther 2015;9:2485–2499. PMID: 25995618.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine — Systematic Review
Vasireddi A et al.
2025 systematic review (PMC12313605) of BPC-157 in orthopaedic sports medicine. Documents VEGFR2, FAK-paxillin, and NO mechanisms. Reviews tendon, ligament, bone, and muscle preclinical data. Notes concentration of published studies from the Zagreb group with limited independent replication. Provides balanced assessment of current evidence quality for musculoskeletal repair research. Contextualizes BPC-157 alongside other tissue repair peptides including thymosin beta-4/TB-500 as complementary mechanisms. Orthop J Sports Med 2025. PMC12313605.
Independent peer-reviewed research — not Trident Labs claims. Both compounds supplied for in vitro research use only. Not for human consumption.
Support
Frequently Asked Questions
Everything you need to know about this product and your order.
